1.47
+0.68%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About MediciNova
From its filings with the US Securities and Exchange Commission
MediciNova is based in La Jolla, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker MNOV. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $409,657 and a net loss of $12.0m. At that date it held total assets of $45.6m and shareholders' equity of $41.6m.
We are a biopharmaceutical company focused on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. Our current strategy is to focus our development activities on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS), and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
We completed a Phase 2b clinical trial of MN-166 (ibudilast) for the treatment of relapsing MS, in which positive safety and neuroprotective efficacy indicators were observed. The data from this trial indicated that MN-166 (ibudilast) may have potential in the treatment of progressive MS.
We partnered with investigators on a Phase 2b clinical trial of MN-166 (ibudilast) in primary progressive and secondary progressive MS which was conducted by NeuroNEXT and funded by the National Institute of Health’s (NIH) National Institute of Neurological Diseases and Stroke (NINDS). This progressive MS trial, known as SPRINT-MS, completed randomization of 255 subjects in 2015, which exceeded the goal of 250 subjects that were planned for participation.
Quoted from its 10-K, filed 10 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 1 Dec 2006
- Employees
- 6
- Website
- medicinova.com ↗
- Head office
- 4275 EXECUTIVE SQUARE, LA JOLLA, CA, 92037
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Yuichi IwakiPresident, Chief Executive Officer, Director, since 2000$1.4m
- Mr. Jason KrugerChief Financial Officer
- Dr. Kazuko MatsudaChief Medical Officer, Director, since 2011$1.0m
- Dr. David CreanChief Business Officer$99,000
- Ms. Carolyn BeaverIndependent Director$57,319
- Ms. Nicole LemerondIndependent Director$57,319
- Mr. Hideki NagaoIndependent Director$57,319
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 29
- Environment
- 29
- Social
- 45
- Governance
- 13
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- MediciNova Inc possesses several strengths that contribute to its competitive advantage in the market. These strengths include:
Weaknesses
- Despite MediciNova Inc's strengths, the company also faces certain weaknesses that could hinder its growth and success. These weaknesses include:
Opportunities
- MediciNova Inc can capitalize on various opportunities in the market to further enhance its business prospects. These opportunities include:
Threats
- MediciNova Inc faces certain threats that could adversely affect its performance and market position. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.